PIA Executive Committee:
Sex and Gender Differences in Alzheimer's Disease
 

Chair: Timothy Hohman
Dr. Timothy Hohman is an Associate Professor of Neurology, cognitive neuroscientist, and computational geneticist, with secondary appointments in the Vanderbilt Genetics Institute and Department of Pharmacology. Dr. Hohman's research leverages advanced computational approaches from genomics, proteomics, and neuroscience to identify novel markers of Alzheimer's disease risk and resilience. Within the Vanderbilt Memory and Alzheimer's Center, Dr. Hohman is the director of the Biomarker Core, oversees the development of neuroimaging, proteomic, and big-data analytical pipelines, and is the Principal Investigator of the Computational Neurogenomics Team focused on Alzheimer's Resilience and Sex Differences. Outside of Vanderbilt, he has directed numerous multi-site collaborative initiatives, with as many as four analysis sites and 40+ contributing universities. Dr. Hohman directs the Genomics Core for the Preclinical Alzheimer's Disease Consortium and is co-chair of the Alzheimer's Disease Sequencing Project (ADSP) Harmonization Consortium. Dr. Hohman's programmatic research focuses on understanding how certain individuals are able to accumulate Alzheimer's disease neuropathology without showing clinical symptoms of the disease. He has identified molecular drivers of such resilience through genomic and proteomic analyses leveraging neuroimaging and neuropathology endophenotypes. Dr. Hohman's team also integrates these diverse data types into a precision medicine approach, focusing on characterizing the best predictors of risk and resilience given an individual's age, sex, genetic, and neuropathological context. Through transdisciplinary collaboration, Dr. Hohman's team seeks to facilitate a more rapid move from genomic discovery to therapeutic development.


Vice Chair: Rachel Buckley
Dr. Rachel Buckley is an Australian cognitive neuroscientist at Massachusetts General Hospital/Brigham and Women’s Hospital (Boston, USA) and is a recipient of an NIH-NIA K99/R00 Pathway to Independence award. Her research is focused on predictive modeling of sex differences in longitudinal cognitive change in older adults who are at genetic and biological risk of Alzheimer’s disease. Her recent work builds on previous literature that suggests women stand at greater risk of progressing to Alzheimer’s disease dementia than men. Specifically, she has become engaged in understanding the underlying biological mechanisms that might underlie female susceptibility (or resilience) to Alzheimer’s disease using positron emission tomography (PET) imaging of the tau protein in the brain. Dr. Buckley is also known in the area of subjective cognitive decline where she wrote her PhD; here, she examined associations between subjective memory concerns and PET AD biomarkers. Dr. Buckley is also co-head of the Healthy Brain Project (healthybrainproject.org.au) with Drs. Yen Ying Lim, Matthew Pase and Nawaf Yassi. The aim of this study is to use digital technology to detect Alzheimer’s disease risk as early as possible in racially and ethnically diverse, and rural, populations across Australia.


Programs Chair: Judy Pa
Dr. Judy Pa is a PhD Cognitive Neuroscientist and Associate Professor at the University of Southern California in the Mark and Mary Stevens Neuroimaging and Informatics Institute and in the departments of Neurology, Neuroscience, and Biomedical Engineering. Dr. Pa has 18 years of human neuroimaging experience and directs a research lab focused on Alzheimer’s risk factors and prevention— with a primary goal of developing and testing new lifestyle interventions for preserving brain health. Dr. Pa is the Imaging Core Co-Leader for USC's Alzheimer’s Disease Research Center and a Project Leader for USC’s Program Project on Vascular Contributions to Alzheimer’s disease. Her active research program includes 2 large ongoing lifestyle intervention trials with a focus on physical and cognitive activities, in addition to understanding Alzheimer’s risk factors, such as sex/gender and APOE4. Her research program is supported by the National Institute on Aging and the Alzheimer’s Association.


Communications Chair: TBA 
Information will be forthcoming.


Early Career Representative: TBA
Information will be forthcoming.


Steering Member – Human: Michelle Mielke
Michelle M. Mielke, Ph.D. received a Bachelor’s of Science in Neuroscience at the University of Pittsburgh and a doctorate in Neuroepidemiology from the Johns Hopkins University Bloomberg School of Public Health. She is currently a Professor in the Department of Health Sciences Research, Division of Epidemiology, and a Professor in the Department of Neurology at the Mayo Clinic in Rochester, MN. Dr. Mielke works as a translational epidemiologist to further understanding of the etiology and epidemiology of neurodegenerative diseases. A primary focus of her research is the identification of fluid biomarkers for the diagnosis, prediction, and progression of Alzheimer's disease and other neurodegenerative diseases. Another focus of Dr. Mielke’s research is on understanding the sex and gender differences in the development and progression of neurodegenerative diseases. She directs the Mayo Clinic Specialized Center of Research Excellence on Sex Differences, with a specific focus on abrupt endocrine disruption, accelerated aging, and Alzheimer’s disease. Dr. Mielke is the past-chair of the Biofluid-Based Biomarker Professional Interest Area under the Alzheimer’s Association, co-Chair of the Society of Women’s Health Alzheimer’s Disease Network, a member of the Food and Drug Administration Peripheral and Central Nervous System Advisory Committee, and Senior Associate Editor of Alzheimer’s and Dementia. She is the PI of several NIH- and Foundation-funded clinical- and epidemiological-based grants. She has published over 200 manuscripts and has presented at multiple national and international conferences and consortiums.


Steering Member – Human: TBA 
Information will be forthcoming.


Steering Member – Non-Human: Roberta Brinton
Information will be forthcoming.

Steering Member – Non-Human: TBA
Information will be forthcoming.

CURRENT ISTAART PIAS 

  Cognition

0